Breast cancer in adolescents and young adults
Breast cancer is the most common cancer of adolescents and young adult (AYA) women
aged 15 to 39 years, accounting for 5.6% of all invasive breast cancer in women. In …
aged 15 to 39 years, accounting for 5.6% of all invasive breast cancer in women. In …
Breast cancer in the 21st century: from early detection to new therapies
JAM Bonilla, MT Tabanera, LHR Mendoza - Radiología (English Edition), 2017 - Elsevier
The analysis of the causes that have given rise to a change in tendency in the incidence and
mortality rates of breast cancer in the last few decades generates important revelations …
mortality rates of breast cancer in the last few decades generates important revelations …
Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2
PURPOSE To estimate the risk of contralateral breast cancer (CBC) among women with
germline pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2 …
germline pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2 …
Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis
K Kerlikowske, AM Molinaro… - Journal of the …, 2010 - academic.oup.com
Background Studies have failed to identify characteristics of women who have been
diagnosed with ductal carcinoma in situ (DCIS) and have a high or low risk of subsequent …
diagnosed with ductal carcinoma in situ (DCIS) and have a high or low risk of subsequent …
Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study
M Stovall, SA Smith, BM Langholz, JD Boice Jr… - International Journal of …, 2008 - Elsevier
PURPOSE: To quantify the risk of second primary breast cancer in the contralateral breast
(CB) after radiotherapy (RT) for first breast cancer. METHODS AND MATERIALS: The study …
(CB) after radiotherapy (RT) for first breast cancer. METHODS AND MATERIALS: The study …
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study
Background Women with a mutation in BRCA1 or BRCA2 have a high risk of developing
breast cancer and of contralateral cancer after the initial diagnosis of breast cancer …
breast cancer and of contralateral cancer after the initial diagnosis of breast cancer …
Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
KA Phillips, RL Milne, MA Rookus, MB Daly… - Journal of clinical …, 2013 - ascopubs.org
Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is
associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 …
associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 …
[图书][B] The vulnerable empowered woman: Feminism, postfeminism, and women's health
TN Dubriwny - 2012 - books.google.com
The feminist women's health movement of the 1960s and 1970s is credited with creating
significant changes in the healthcare industry and bringing women's health issues to public …
significant changes in the healthcare industry and bringing women's health issues to public …
Second primary cancer risk-the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study
A Coyte, DS Morrison, P McLoone - BMC cancer, 2014 - Springer
Background There is evidence that cancer survivors are at increased risk of second primary
cancers. Changes in the prevalence of risk factors and diagnostic techniques may have …
cancers. Changes in the prevalence of risk factors and diagnostic techniques may have …
Incidence and prognosis of synchronous and metachronous bilateral breast cancer
M Hartman, K Czene, M Reilly, J Adolfsson… - Journal of Clinical …, 2007 - ascopubs.org
Purpose Because the incidence of breast cancer is increasing and prognosis is improving, a
growing number of women are at risk of developing bilateral disease. Little is known …
growing number of women are at risk of developing bilateral disease. Little is known …